Safety of Tasfygo in biliary tract cancer with an FGFR2 fusion gene
Studies the safety of Tasfygo in people with biliary tract cancer and an FGFR2 fusion.
Plain-language title generated from the registry record
Registry title: A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Key facts
- Where
- Tokyo, JapanSee the site
Where in Japan
- TokyoTokyo, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eisai Co., Ltd.
- Trial code
- NCT06793709
- Record updated
- 27 February 2026
- Original description
The primary purpose of this study is to investigate the safety of Tasfygo.Read full original descriptionShow less
Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy
The primary purpose of this study is to investigate the safety of Tasfygo.
Inclusion: Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
Exclusion: Not applicable.